Company Overview of OvaScience, Inc.
OvaScience, Inc., a life science company, engages in the discovery, development, and commercialization of new treatments for infertility. The company’s patented technology is based on the discovery of egg precursor (EggPC) cells, which are immature egg cells found in the protective outer layer of a woman's own ovaries. It is developing and commercializing various fertility treatment options designed to enhance egg health and revolutionize in vitro fertilization (IVF) comprising AUGMENT to improve the energy and health of the woman’s eggs by using mitochondria from a woman's EggPC cells; OvaPrime treatment for boosting a woman's egg reserve by transferring the EggPCs from woman's own ovaries;...
215 First Street
Cambridge, MA 02142
Founded in 2011
Key Executives for OvaScience, Inc.
Co-Founder, Chief Executive Officer and Director
President and Chief Scientific Officer
Total Annual Compensation: $644.0K
Compensation as of Fiscal Year 2014.
OvaScience, Inc. Key Developments
OvaScience, Inc. Reports Unaudited Consolidated Earnings Results for the Third Quarter and Nine Months Ended September 30, 2015
Nov 5 15
OvaScience, Inc. reported unaudited consolidated earnings results for the third quarter and nine months ended September 30, 2015. Net loss for the three months ended September 30, 2015 was $17.9 million, or $0.66 per basic and diluted share, as compared to net loss of $12.9 million, or $0.54 per basic and diluted share, for the three months ended September 30, 2014. The increase in net loss is primarily attributable to planned higher personnel costs, stock-based compensation, and costs associated with the launch of the AUGMENT treatment in certain international IVF clinics. For the quarter, the company reported revenue of $0.075 million. Loss from operations was of $17.772 million compared to $12.399 million a year ago.
For nine months, the company reported revenue of $0.120 against $0.00 a year ago. Loss from operations was of $51.759 million compared to $29.644 million a year ago. Net loss was $52.618 million or $1.95 per basic and diluted share compared to $30.630 million or $1.38 per basic and diluted share a year ago.
OvaScience, Inc. - Special Call
Sep 28 15
To provide an update on corporate goal for AUGMENT Treatment
OvaScience, Inc. Presents at Boston Biotech Conferences 2015, Nov-11-2015
Sep 22 15
OvaScience, Inc. Presents at Boston Biotech Conferences 2015, Nov-11-2015. Venue: Apella, 450 East 29th Street, NY 10016, New York, United States. Presentation Date & Speakers: Nov-11-2015, Theresa McNeely, Chief Communications Officer and Executive Vice President. Nov-12-2015, Arthur Tzianabos, President and Chief Scientific Officer.
Similar Private Companies By Industry
Recent Private Companies Transactions
|No transactions available in the past 12 months.|